Skip to main content

Zymeworks Inc(ZYME-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume

Latest News

Zymeworks Provides Corporate Update and Reports Second Quarter 2022 Financial Results
Business Wire - Thu Aug 4, 3:15PM CDT
Business Wire
Thu Aug 4, 3:15PM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the second quarter ended June 30, 2022.
Zymeworks Announces Participation in Upcoming Investor Conferences
Business Wire - Mon Aug 1, 7:30AM CDT
Business Wire
Mon Aug 1, 7:30AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
Zymeworks Announces Oral Presentation of Data from Phase 1 Study of Zanidatamab Zovodotin (ZW49) in Solid Cancers at European Society for Medical Oncology (ESMO) Congress 2022 in Paris
Business Wire - Mon Jul 25, 7:30AM CDT
Business Wire
Mon Jul 25, 7:30AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that data from the company’s Phase 1 study of zanidatamab zovodotin (ZW49), an investigational novel bispecific...
Zymeworks Reports Inducement Grant to New Chief Scientific Officer
Business Wire - Fri Jul 22, 7:30AM CDT
Business Wire
Fri Jul 22, 7:30AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the “NYSE Rule”), an equity...
Zymeworks to Host Second Quarter Results Conference Call
Business Wire - Thu Jul 21, 7:30AM CDT
Business Wire
Thu Jul 21, 7:30AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its second quarter 2022 financial results after market close on August 4 th , 2022....
Zymeworks Announces Plan to Become a Delaware Corporation
Business Wire - Fri Jul 15, 7:00AM CDT
Business Wire
Fri Jul 15, 7:00AM CDT
Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced its intention to become a Delaware corporation (“New Zymeworks”), subject to receipt...
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
Business Wire - Mon Jun 27, 7:30AM CDT
Business Wire
Mon Jun 27, 7:30AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as...
Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
Business Wire - Mon Jun 27, 7:30AM CDT
Business Wire
Mon Jun 27, 7:30AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, Ph.D., as...
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
Business Wire - Fri Jun 10, 8:15AM CDT
Business Wire
Fri Jun 10, 8:15AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that its board of directors (the “Board”) has adopted a limited-duration shareholder rights plan...
Zymeworks Announces Participation in Upcoming Investor Conference
Business Wire - Fri May 27, 4:30AM CDT
Business Wire
Fri May 27, 4:30AM CDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference: